Cel-Sci Corporation (CVM) financial statements (2020 and earlier)

Company profile

Business Address 8229 BOONE BLVD .
VIENNA, VA 22182
State of Incorp. CO
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments981023
Cash and cash equivalents981023
Receivables00000
Inventory, net of allowances, customer advances and progress billings11111
Inventory11111
Prepaid expense01011
Deposits current assets   00
Total current assets:11101145
Noncurrent Assets
Finance lease, right-of-use asset13 
Operating lease, right-of-use asset1 
Property, plant and equipment316161717
Intangible assets, net (including goodwill)00000
Intangible assets, net (excluding goodwill)00000
Other undisclosed noncurrent assets22222
Total noncurrent assets:1918181919
TOTAL ASSETS:3028302325
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities22693
Accounts payable12683
Accrued liabilities00010
Debt   1 
Derivative instruments and hedges, liabilities1120 
Due to related parties11111
Other liabilities00000
Other undisclosed current liabilities1    
Total current liabilities:539114
Noncurrent Liabilities
Long-term debt and lease obligation13    
Finance lease, liability12 
Operating lease, liability1 
Liabilities, other than long-term debt56728
Other liabilities00000
Derivative instruments and hedges, liabilities56728
Other undisclosed noncurrent liabilities 14141313
Total noncurrent liabilities:1819201522
Total liabilities:2322302626
Stockholders' equity
Stockholders' equity attributable to parent750(3)(1)
Common stock00000
Additional paid in capital366359331296285
Accumulated deficit(359)(354)(332)(300)(285)
Total stockholders' equity:750(3)(1)
TOTAL LIABILITIES AND EQUITY:3028302325

Income statement (P&L) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Gross profit:(0)0000
Operating expenses(24)(21)(17)(21)(24)
Other undisclosed operating income100  
Operating loss:(23)(20)(17)(21)(24)
Nonoperating income (expense)(0)1  (2)
Investment income, nonoperating21   
Interest and debt expense  (0)  
Loss from continuing operations before income taxes:(24)(20)(17)(21)(26)
Other undisclosed income from continuing operations    2
Net loss:(24)(20)(17)(21)(24)
Other undisclosed net income (loss) attributable to parent(3)(2)(15)712
Net loss attributable to parent:(27)(22)(32)(14)(12)
Other undisclosed net loss available to common stockholders, basic  (0)(0) 
Net loss available to common stockholders, basic:(27)(22)(32)(14)(12)
Other undisclosed net loss available to common stockholders, diluted   (1) 
Net loss available to common stockholders, diluted:(27)(22)(32)(15)(12)

Comprehensive Income ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Net loss:(24)(20)(17)(21)(24)
Comprehensive loss, net of tax, attributable to parent:(24)(20)(17)(21)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: